Collaboration is vital to support innovation in the microbiome arena and ensure that products get to patients as swiftly as possible. This interactive workshop, featuring short presentations and roundtable discussions, allows you to connect with like-minded individuals to overcome some of the key bottlenecks in the regulation of microbiome-based drugs, including: clinical trial design, endpoint and biomarker selection, use of expedited review pathways and product nomenclature.

• Considerations for reducing the intensiveness of resource consumption during early bioprocessing developments.
• Prioritization of the fundamental variables of bioprocessing developments to accelerate effective product development.
• Discussing ‘good to haves’ vs ‘essentials’ in the development of live biotherapeutic products without impeding quality.

Characterizing the considerations for capsule drug delivery of GEMMs demonstrating long-term patterns of bacterial engraftment. Identifying the bacterial communities successfully engrafted through genomic methods.

• PharmaBiome's NicheMap™ technology maps bacteria into functional niches taking into account the relevant complex context of intestinal microbiota
• The NicheMap™ provides an evidence-based selection rationale for strains that make up out metabolically interacting LBP consortia
• We produce these ecologically engineered consortia using cocultivation with PharmaBiome's C3 technology
• The NicheMap™ and C3 produce consortia with strong control over pharmacokinetics and pharmacodynamics

• Discussing the application of in-silico simulation (CarbonMirror Platform) to bioprocessing
• Understanding the limitations and benefits of in-silico simulation, choosing the optimum conditions for maximum yield and tackling biofilms